搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
1 小时
on MSN
23andMe customer? Here's what to know about the privacy of your genetic data.
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
1 天
on MSN
23andMe is ending its cancer research program and slashing over 200 jobs
23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s ...
6 小时
23andMe宣布重组并转变重点
23andMe Holding Co.(纳斯达克股票代码:ME)在最近的财报电话会议上概述了战略转变,强调削减成本并转向基于订阅的收入和制药合作伙伴关系。公司的重组努力,包括大幅裁员和终止治疗项目,是提高长期可持续性和财务健康的更广泛战略的一部分。尽管面临收入和现金储备下降的问题,23andMe正在采取措施改善其财务状况并重新获得投资者信心。
23 小时
on MSN
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...
1 天
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...
1 天
on MSN
23andMe announces layoffs totaling 40% of workforce, discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...
Yahoo
23 小时
23AndMe to lay off 40% of staff
The genealogy company’s CEO announced over 200 employees will be let go and it will also shutter its drug-development arm. I ...
1 天
on MSN
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies ...
1 天
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire ...
1 天
23andMe股价下跌,第二季度亏损扩大尽管收入超预期
加利福尼亚州桑尼维尔 - 23andMe Holding Co. (NASDAQ:ME) 公布的2024财年第二季度亏损超出预期,尽管收入超过预估,导致盘后交易中股价下跌1.74%。 这家基因和预防性健康公司在截至9月30日的季度内每股亏损2.32美元,远高于分析师预期的每股亏损0.16美元。然而,收入达到4407万美元,超过了3641万美元的一致预期。
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈